Evidence map›Paper›PMID 38655602›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2024

Discovery of novel FGFR4 inhibitors through a build-up fragment strategy.

Jihyung Kim, Chang Gyun Im, Kyujin Oh, Ji Min Lee, Fatimah Al-Rubaye, Kyung Hoon Min

Open access · goldAbstract read
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jihyung KimCollege of Pharmacy, Chung-Ang University, Seoul, Republic of Korea.
Chang Gyun ImCollege of Pharmacy, Chung-Ang University, Seoul, Republic of Korea.
Kyujin OhCollege of Pharmacy, Chung-Ang University, Seoul, Republic of Korea.
Ji Min LeeCollege of Pharmacy, Chung-Ang University, Seoul, Republic of Korea.
Fatimah Al-RubayeCollege of Pharmacy, Chung-Ang University, Seoul, Republic of Korea.
Kyung Hoon MinCollege of Pharmacy, Chung-Ang University, Seoul, Republic of Korea.
Chung-Ang University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death. FGFR4 has been implicated in HCC progression, making it a promising therapeutic target. We introduce an approach for identifying novel FGFR4 inhibitors by sequentially adding fragments to a common warhead unit. This strategy resulted in the discovery of a potent inhibitor,

Indexed as

Dose-Response Relationship, DrugDrug DiscoveryReceptor, Fibroblast Growth Factor, Type 4Antineoplastic AgentsCarcinoma, HepatocellularCell ProliferationDrug Screening Assays, AntitumorHumansMolecular StructureProtein Kinase InhibitorsStructure-Activity RelationshipAntineoplastic AgentsFGFR4 protein, humanProtein Kinase InhibitorsReceptor, Fibroblast Growth Factor, Type 4FGFR4fragmenthit identificationkinase inhibitorsmall molecule

Identifiers

PMID38655602
PMCPMC11044719
OpenAlexW4395116424

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.